About Xeno Biosciences
Xeno Biosciences is a private company based in Cambridge, Massachusetts. It has reported $12,096,538 raised in four offerings on Form D since August 2018. Its chief executive is David Beno.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Dec 22, 2022 | Jan 5, 2023 | $1,500,000fully sold | 64 | $23,438 | DebtRule 506(b) | Form D ↗ |
| Jul 22, 2021 | Aug 3, 2021 | $9,426,538of $9.9M target | 133 | $70,876 | EquityRule 506(b) | Form D ↗ |
| Feb 1, 2019 | Feb 8, 2019 | $720,000of $1.6M target | 21 | $34,286 | Debt, OptionsRule 506(b) | Form D ↗ |
| Jul 5, 2018 | Aug 3, 2018 | $450,000fully sold | 20 | $22,500 | Equity, OptionsRule 506(b) | Form D ↗ |
| Total, four offerings | $12,096,538 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Xeno Biosciences's Form D filed Jan 5, 2023.
DB
David Beno
Chief Executive Officer and director
JA
Jeffrey Arnold
Director
MK
Michael Koeris
Director
TH
Tom Hughes
Director
SR
Stan Rose
Director
Earlier filings also listed Hasan Celiker (ceo and director, last listed Feb 2019).